Everest Medicines (STU:6HN) Research & Development: €61.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6HN Everest Medicines Ltd STU:6HN
51 GF Score
Price €2.80
GF Value €32.66
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Everest Medicines Research & Development?

Everest Medicines STU:6HN -0.71% 51 Research & Development is €61.9 Mil as of Dec. 2025. GuruFocus rates STU:6HN with a GF Score™ of 51/100 and a GF Value™ of €32.66 (Possible Value Trap). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Everest Medicines's Research & Development for the six months ended in Dec. 2025 was €38.3 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €61.9 Mil.

Everest Medicines  (STU:6HN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Everest Medicines Research & Development Related Terms

Everest Medicines Research & Development Historical Data

* Premium members only.

The historical data trend for Everest Medicines's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Research & Development Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 85.24 109.64 69.36 69.26 61.96

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.31 32.42 36.06 23.57 38.29
STU:6HN
51GF Score
Everest Medicines Ltd STU:6HN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Everest Medicines Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €61.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €61.9 Mil mean?
Everest Medicines (STU:6HN) has a Research & Development of €61.9 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Everest Medicines and its competitors.
Is Everest Medicines' Research & Development too high?
Everest Medicines' current Research & Development is €61.9 Mil. Overall, Everest Medicines has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Research & Development compare to VRTX and REGN?
Everest Medicines' Research & Development of €61.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Everest Medicines and its competitors. Everest Medicines's current Research & Development is €61.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (STU:6HN) is currently considered Possible Value Trap. The stock's GF Value™ is €32.66, compared to a current price of €2.80 — trading 91.4% below its estimated fair value. The current Research & Development is €61.9 Mil. Everest Medicines' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Everest Medicines (STU:6HN), the current Research & Development is €61.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Everest Medicines (STU:6HN) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of €2.80 is trading 91.4% below its estimated GF Value™ of €32.66. GuruFocus considers Everest Medicines to be Possible Value Trap.

Key valuation signals for STU:6HN:

  • Research & Development: €61.9 Mil
  • GF Value™: €32.66 vs. price of €2.80 (91.4% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Everest Medicines Business Description

Other Exchanges 01952:Hong Kong
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
51GF Score

Get the complete analysis for STU:6HN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.80
Price
€32.66
GF Value